Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma

In patients with treatment-naive diffuse large B-cell lymphoma (DLBCL), the POLARIX study (A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone [R-CHP] Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone...

Descripción completa

Detalles Bibliográficos
Autores principales: Kambhampati, Swetha, Saumoy, Monica, Schneider, Yecheskel, Pak, Stacy, Budde, Lihua Elizabeth, Mei, Matthew G., Siddiqi, Tanya, Popplewell, Leslie L., Wen, Yi-Ping, Zain, Jasmine, Forman, Stephen J., Kwak, Larry W., Rosen, Steven T., Danilov, Alexey V., Herrera, Alex F., Thiruvengadam, Nikhil R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653095/
https://www.ncbi.nlm.nih.gov/pubmed/35700381
http://dx.doi.org/10.1182/blood.2022016624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10653095/
https://www.ncbi.nlm.nih.gov/pubmed/35700381
http://dx.doi.org/10.1182/blood.2022016624

Ejemplares similares